p53-dependent repression of polo-like kinase-1 (PLK1)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PLK1 is a critical mediator of G₂/M cell cycle transition that is inactivated and depleted as part of the DNA damage-induced G₂/M checkpoint. Here we show that downregulation of PLK1 expression occurs through a transcriptional repression mechanism and that p53 is both necessary and sufficient to mediate this effect. Repression of PLK1 by p53 occurs independently of p21 and of arrest at G₁/S where PLK1 levels are normally repressed in a cell cycle-dependent manner through a CDE/CHR element. Chromatin immunoprecipitation analysis indicates that p53 is present on the PLK1 promoter at two distinct sites termed p53RE1 and p53RE2. Recruitment of p53 to p53RE2, but not to p53RE1, is stimulated in response to DNA damage and/or p53 activation and is coincident with repression-associated changes in the chromatin. Downregulation of PLK1 expression by p53 is relieved by the histone deacetylase inhibitor, trichostatin A, and involves recruitment of histone deacetylase to the vicinity of p53RE2, further supporting a transcriptional repression mechanism. Additionally, wild type, but not mutant, p53 represses expression of the PLK1 promoter when fused upstream of a reporter gene. Silencing of PLK1 expression by RNAi interferes with cell cycle progression consistent with a role in the p53-mediated checkpoint. These data establish PLK1 as a direct transcriptional target of p53, independently of p21, that is required for efficient G₂/M arrest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 3×
“5A): the latter site contains two contiguous canonical p53 half-sites.(5) Accordingly, PCR primers were designed to permit analysis of each of these two regions.”
Background
Research works printed but not linked: 44
- Vousden KH, 2007, Nat Rev, 8, 275, 10.1038/nrm2147 · DOI · Paper page
- 10.1101/cshperspect.a001883 · DOI · Paper page
- 10.1038/sj.onc.1204252 · DOI · Paper page
- Imbriano C, 2005, Mol Cell Biol, 25, 3737, 10.1128/MCB.25.9.3737-3751.2005 · DOI · Paper page
- Martin BT, 2006, Cell Cycle, 5, 2881, 10.4161/cc.5.24.3538 · DOI
- Saint Clair S, 2006, Cell Cycle, 5, 709, 10.4161/cc.5.7.2628 · DOI
- 10.1038/nrm2653 · DOI · Paper page
- Fenton B, 1993, Nature, 363, 637, 10.1038/363637a0 · doi:10.1038/363637a0
- Glover DM, 1998, Genes Dev, 12, 3777, 10.1101/gad.12.24.3777 · DOI · Paper page
- 10.1038/nrc1841 · DOI · Paper page
- Yim H, 2009, Mol Cell Biol, 29, 2609, 10.1128/MCB.01277-08 · DOI
- Golsteyn RM, 1994, J Cell Sci, 107, 1509, 10.1242/jcs.107.6.1509 · DOI · Paper page
- Hamanaka R, 1995, J Biol Chem, 270, 21086, 10.1074/jbc.270.36.21086 · DOI · Paper page
- Lee KS, 1995, Mol Cell Biol, 15, 7143, 10.1128/MCB.15.12.7143 · DOI · Paper page
- Uchiumi T, 1997, J Biol Chem, 272, 9166, 10.1074/jbc.272.6.3302 · DOI
- Smith MR, 1997, Biochem Biophys Res Commun, 234, 397, 10.1006/bbrc.1997.6633 · DOI · Paper page
- St Clair S, 2004, Mol Cell, 16, 725, 10.1016/j.molcel.2004.11.002 · DOI · Paper page
- 10.1038/sj.onc.1208617 · DOI · Paper page
- Ando K, 2004, J Biol Chem, 279, 25549, 10.1074/jbc.M314182200 · DOI · Paper page
- 10.1038/35023629 · DOI · Paper page
- 10.1074/jbc.M101831200 · DOI · Paper page
- Incassati A, 2006, Oncogene, 25, 2444, 10.1038/sj.onc.1209276 · DOI
- Kho PS, 2004, J Biol Chem, 279, 21183, 10.1074/jbc.M311912200 · DOI · Paper page
- 10.1073/pnas.0813333106 · DOI · Paper page
- Zhu H, 2002, Cell Cycle, 1, 59
- 10.1016/j.molcel.2004.07.015 · DOI · Paper page
- Bates GJ, 2005, EMBO J, 24, 543, 10.1038/sj.emboj.7600550 · DOI · Paper page
- Hupp TR, 1992, Cell, 71, 875, 10.1016/0092-8674(92)90562-Q · DOI · Paper page
- 10.1101/gad.8.10.1235 · DOI · Paper page
- 10.1128/MCB.26.9.3492-3504.2006 · DOI · Paper page
- 10.1074/jbc.M106643200 · DOI · Paper page
- Lee KC, 1999, Mol Cell Biol, 19, 1279, 10.1128/MCB.19.2.1279 · DOI · Paper page
- Guan R, 2005, Cancer Res, 65, 2698, 10.1158/0008-5472.CAN-04-2131 · DOI
- Kreis NN, 2009, Cell Cycle, 8, 460, 10.4161/cc.8.3.7651 · DOI
- Liu X, 2002, Proc Natl Acad Sci USA, 99, 8672, 10.1073/pnas.132269599 · DOI
- Liu X, 2003, Proc Natl Acad Sci USA, 100, 5789, 10.1073/pnas.1031523100 · DOI · Paper page
- Liu X, 2006, Mol Cell Biol, 26, 2093, 10.1128/MCB.26.6.2093-2108.2006 · DOI · Paper page
- Spankuch-Schmitt B, 2002, J Natl Cancer Inst, 94, 1863, 10.1093/jnci/94.24.1863 · DOI · Paper page
- Spankuch-Schmitt B, 2002, Oncogene, 21, 3162, 10.1038/sj.onc.1205412 · DOI
- Stark GR, 2006, Mol Biotechnol, 32, 227, 10.1385/MB:32:3:227 · DOI · Paper page
- Young V, 2002, Rheumatology, 41, 869, 10.1093/rheumatology/41.8.869 · doi:10.1093/rheumatology/41.8.869
- Midgley CA, 1992, J Cell Sci, 101, 183, 10.1242/jcs.101.1.183 · DOI · Paper page
- Kowalik TF, 1998, Cell Growth Differ, 9, 113
- Schumm K, 2006, EMBO J, 25, 4820, 10.1038/sj.emboj.7601343 · DOI
Cited by
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
PLK1, A Potential Target for Cancer Therapy
Liu, Z., Sun, Q., & Wang, X. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.10.003 · Cited by 454
DNA Damage Response Genes and the Development of Cancer Metastasis
Broustas, C. G., & Lieberman, H. B. (2014) · Radiation Research · doi:10.1667/rr13515.1 · Cited by 275
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
Carvajal, L. A., Hamard, P.-J., Tonnessen, C., & Manfredi, J. J. (2012) · Genes & Development · doi:10.1101/gad.184911.111 · Cited by 151
“The ‘‘direct’’ model of repression involves the binding of p53 to a putative p53 response element on specific repression target genes (Lee et al. 1999, 2001; Murphy et al. 1999; St Clair et al. 2004; McKenzie et al. 2010; Wang et al. 2010).”
BackgroundThe transcription factor p53: Not a repressor, solely an activator.
Fischer, M., Steiner, L., & Engeland, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949083 · Cited by 153
Quaas, M., Müller, G. A., & Engeland, K. (2012) · Cell Cycle · doi:10.4161/cc.22917 · Cited by 107
Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing
Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz006 · Cited by 50
Metadata
- Authors
- McKenzie, L., King, S., Marcar, L., Nicol, S., Dias, S. S., Schumm, K., Robertson, P., Bourdon, J.-C., Perkins, N., Fuller-Pace, F., & Meek, D.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2010-10-15
- Volume
- 9
- Issue
- 20
- Pages
- 4200-4212
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2071748938
- Cited by
- 117
- References
- 5
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.